Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: AP Photos
The White House has withdrawn the nomination of physician and presidential adviser Dr. Heidi Overton to lead the Food and Drug Administration (FDA), ending her bid for the top regulatory post just a day before a scheduled Senate committee vote.
Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.
“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy wrote on X shortly after the withdrawal.
A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.”
Also read: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA
The nomination faced growing resistance from Republican members of the 21-member Senate committee. Overton needed the support of all 12 Republicans to advance, assuming all 11 Democrats voted against her.
Several Republican senators had not committed to supporting her, including Cassidy, Susan Collins and Lisa Murkowski. The uncertainty left the White House struggling to secure the votes needed ahead of the November 18 committee hearing.
Cassidy, however, maintained that Overton was close to securing enough support. Calling the withdrawal “odd,” he said he had been having productive conversations with senators and believed she could have cleared both the committee and the full Senate.
Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation
Overton faced opposition over her positions on vaccine policy, abortion medication and vaping, exposing divisions among Republicans and the MAHA movement.
Vaccine policy: Cassidy questioned her role in Trump's efforts to change childhood vaccine recommendations, including splitting the combined measles, mumps and rubella (MMR) vaccine. Overton maintained that the MMR vaccine was safe and effective and said she would follow FDA safety requirements.
Mifepristone restrictions: Anti-abortion groups and Republican Sen. Josh Hawley questioned her commitment to tightening restrictions on mifepristone, the abortion pill. Meanwhile, Republican senators Susan Collins and Lisa Murkowski raised concerns about her strong anti-abortion positions.
Flavoured vapes: Overton faced criticism for her role in the administration's authorisation of fruit-flavoured e-cigarettes. Opponents even launched a campaign using the label “Heidi Vaperton” to urge senators to reject her nomination.
MAHA backlash: Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement accused Overton of being too close to corporate and agricultural interests. Former White House adviser Calley Means alleged that her decisions on glyphosate and flavoured vapes conflicted with Kennedy's agenda.
Overton is a physician and former deputy director of the White House Domestic Policy Council. Before her nomination, she worked at the conservative think tank America First Policy Institute, where she eventually led its Health Policy Center.
She received her medical degree from the University of New Mexico, completed general surgery training at Johns Hopkins University and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.
She also served during Trump's first administration before joining the think tank.
Overton was involved in several prominent health policy initiatives under the current administration, including efforts to redesign the food pyramid, overhaul childhood vaccine recommendations and negotiate prescription drug pricing deals.
The withdrawal leaves the FDA without a Senate-confirmed commissioner. Acting Commissioner Kyle Diamantas has been leading the agency since Makary resigned in May.
The administration is now considering potential replacements, including Republican Senator Roger Marshall of Kansas, according to Reuters. No new nominee has been formally announced.
Credit: AI image
Amid growing research in vaccination for different cancers, an experimental cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML) in a late-stage clinical trial.
Showing promise in treating the aggressive blood cancer, the findings have given hope to patients whose cancer has returned after treatment and those who have limited options.
The vaccine, called galinpepimut-S (GPS), is being developed by US-based pharma company SELLAS Life Sciences. Results from the Phase 3 REGAL trial showed that patients who received the vaccine lived longer than those given the next best available treatment.
Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. It develops when abnormal immature blood cells multiply rapidly and interfere with the production of healthy red blood cells, white blood cells and platelets.
Common symptoms include persistent fatigue, fever, frequent infections, easy bruising, unusual bleeding and breathlessness.
Treatment usually involves chemotherapy, specific medicines in eligible patients and in some cases, stem-cell transplantation. AML can return after treatment, making it difficult to achieve remission.
The trial involved 126 patients who had achieved remission after treatment but were unable to undergo a stem-cell transplant.
According to the findings, the vaccine reduced the risk of death by 41%. Patients receiving GPS had a median overall survival of 24 months, compared to 14.7 months among those receiving standard treatment. The results also showed a hazard ratio of 0.59 and a p-value of 0.035.
SELLAS plans to discuss the findings with the US Food and Drug Administration (FDA), preparing to submit an application for approval in the first half of 2027.
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Unlike preventive vaccines, GPS is a therapeutic cancer vaccine. It is developed to help immune system identify and destroy residual cancer cells in the body after treatment.
The vaccine targets a protein called Wilms' Tumour 1 (WT1), which is found in more than 95% of people with AML, according to Memorial Sloan Kettering Cancer Center (MSK), where the vaccine was developed.
GPS contains synthetic peptides, which are short chains of amino acids derived from the WT1 protein. These peptides help the immune system to produce specialised T cells that recognise and attack cancer cells carrying WT1.
In simple terms, the vaccine trains the immune system to identify leftover cancer cells that may be too small to detect through routine testing but could eventually cause cancer recurrence.
Unlike personalised cancer vaccines that are manufactured using an individual patient's tumour, GPS is an off-the-shelf vaccine that can be used in multiple patients.
GPS was generally tolerated well in the Phase 3 trial as no safety concerns were identified. Most side effects were mild to moderate. Reactions at injection sites were among the most commonly reported side effects.
The company, however, has only announced topline results. The detailed findings from the trial's secondary endpoints related to relapse-free and leukemia-free survival, will be presented at a future medical conference.
If the findings are supported by regulatory authorities, GPS could become a new treatment option for patients whose AML has relapsed and those who cannot opt for a stem-cell transplant.
Credit: AI image
The United States is not the only country to lose its measles elimination status this year. Mexico and Bolivia have also lost the status after the highly contagious virus continued spreading for more than 12 months, according to the Pan American Health Organization (PAHO).
The decision was formally announced on November 17, 2026 by PAHO's independent Regional Monitoring and Re-Verification Commission, which reviewed measles data from 47 countries and territories across the Americas.
The United States had maintained its measles elimination status since 2000, while Mexico and Bolivia had also previously interrupted sustained local transmission. The latest development marks a setback in efforts to control a disease that can be prevented through vaccination.
The announcement comes as measles cases continue to rise across the region. As of November 13, 2026, the Americas had reported 58,213 confirmed cases and 82 deaths, compared with 12,806 cases during the same period in 2025.
Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC
According to PAHO, a country loses its measles elimination status when the same measles virus genotype and lineage circulates continuously within its borders for at least 12 months. This indicates that the virus has re-established endemic transmission rather than appearing only through isolated cases imported from other countries.
According to PAHO, the sustained transmission periods in the three countries began on different dates:
Losing elimination status does not mean that measles is spreading everywhere within these countries. It means that the same virus lineage has continued circulating locally for at least a year.
The Americas had previously lost its regional measles elimination status in November 2025, after Canada reported to have sustained transmission for more than 12 months. The region had first eliminated measles in 2016 and regained that achievement in 2024 after stopping transmission in Venezuela and Brazil.
Also read: US Loses Measles Elimination Status After 26 Years: What Does It Mean?
After PAHO's announcement, US Health and Human Services Secretary Robert F. Kennedy Jr and Centers for Disease Control and Prevention (CDC) Director Dr Erica Schwartz issued separate statements.
Kennedy said the administration would continue working to control outbreaks and restore the country's elimination status.
"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," he said in a statement. He also expressed his support for vaccination, adding, "I continue to recommend MMR vaccination as the most effective way to prevent measles."
Kennedy attributed gaps in childhood immunisation to disruptions during the COVID-19 pandemic which affected routine vaccination programmes in the US and other countries.
He also said that approximately $100 million in additional CDC funding has been provided since August to strengthen measles prevention and outbreak response. The funding is intended to support state and local health departments, improve surveillance and help close vaccination gaps.
CDC Director Dr Schwartz said the loss of the designation would not change the agency's approach to controlling the disease.
"The measles elimination designation is not what protects Americans. Vaccination does. We know where transmission is occurring and we've invested $100 million in state and local health departments to reach those communities," she said.
"Losing a designation doesn't mean we abandon an evidence-based approach. It means we remain focused on stopping outbreaks."
Also read: RFK Jr's Vaccine Controversy: What His Samoa Trip Has To Do With 83 Measles Deaths
The latest PAHO figures highlight the scale of the resurgence. The region recorded more than four times as many confirmed measles cases by November 13, 2026 as during the corresponding period in 2025.
Mexico has reported more than 13,900 confirmed cases so far in 2026, the highest annual total since the 1989-90 epidemic. The US has recorded more than 5,400 cases and 10 deaths, its highest in more than 35 years. Bolivia has reported more than 100 cases.
Amid the resurgence, a CDC report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
Measles is among the most contagious infectious diseases. One infected person can transmit the virus to as many as 18 people who are susceptible to infection.
The disease typically causes fever, cough, a runny nose, red and watery eyes, followed by a characteristic skin rash. However, it can also lead to serious complications, including pneumonia, brain inflammation (encephalitis), blindness and death. It can also weaken the immune system for months after infection.
PAHO expects the US, Mexico and Bolivia to submit plans outlining how they plan to interrupt transmission and strengthen measles vaccination and surveillance.
The organisation has called on countries across the Americas to achieve and maintain at least 95% coverage with both doses of the measles vaccine.
The MMR vaccine, which protects against measles, mumps and rubella, remains the most effective way to prevent measles.
© $2026 Times Horizon Private Limited